Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

[EX Q]: In a phase I study, Gilead Sciences' PI3K- inhibitor idelalisib produced rapid tumor shrinkage-a response that lasted for 17 months on average-in about half of the 54 patients with chronic lymphocytic leukemia who participated.
[EX A]: What is the target protein of the drug Idelalisib?

[EX Q]: In the mean time, Maha Nawrahta opened the southern front on 23 October 1765 in three directions. He had 20,000 to 30,000 under his command. A small army invaded by the Three Pagodas Pass towards Suphanburi. Another small army invaded down the Tenasserim coast towards Mergui and Tenasserim town. However, the main thrust of his attack was at Kanchanaburi. His 20,000-strong main southern army invaded via the Myitta Pass. Kanchanaburi fell with little resistance. The main reason for the quick fall of Kanchanaburi could be that the Burmese were more battle-hardened. But it could also be that the Siamese command miscalculated where the Burmese main attack would come from, and had not sufficiently reinforced the fort to withstand a major attack. Judging by the Siamese chronicles' reporting of the main attack route, the Siamese command appeared to have believed that the main Burmese attack would come from the Gulf of Siam coastline, instead of the most obvious and shortest route via Kanchanaburi. The Siamese sources say that Maha Nawrahta's main invasion route came from southern Tenasserim, crossing the Tenasserim range at Chumphon and Phetburi. The path is totally different from the Kanchanaburi route reported by the Burmese chronicles. Historian Kyaw Thet specifically adds that the main attack route was via the Myitta Pass.
[EX A]: How many Maha Nawrahta opened the southern front?

[EX Q]: Microbicides are being developed in order to prevent sexual transmission of HIV. Dapivirine, a non-nucleoside reverse transcriptase inhibitor, is one of the leading drug candidates in the field, currently being tested in various dosage forms, namely vaginal rings, gels, and films. In particular, a ring allowing sustained drug release for 1month is in an advanced stage of clinical testing. Two parallel phase III clinical trials are underway in sub-Saharan Africa and results are expected to be released in early 2016. This article overviews the development of dapivirine and its multiple products as potential microbicides, with particular emphasis being placed on clinical evaluation. Also, critical aspects regarding regulatory approval, manufacturing, distribution, and access are discussed.
[EX A]:
Which infection can be prevented with Dapivirine?